PTC Therapeutics (PTCT) Misses Q3 EPS by 22c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
PTC Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update
November 2, 2017 4:01 PM EDTSOUTH PLAINFIELD, N.J., Nov. 2, 2017 /PRNewswire/ --Â PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the third quarter ending September 30, 2017.
"Our performance this quarter combined with our commercial, financial and R&D advancements should allow us to end 2017 in a strong position," said Stuart W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. "Our commercial success is driven by our mission of improving the lives of patients with Duchenne."
Third Quarter Financial Highlights:
Translarna net product sales were... More